|1.||Kanse, Sandip M: 15 articles (04/2015 - 04/2004)|
|2.||Preissner, Klaus T: 9 articles (06/2009 - 04/2004)|
|3.||Bernardi, Francesco: 7 articles (03/2012 - 02/2002)|
|4.||Girolami, A: 6 articles (01/2013 - 06/2000)|
|5.||Hedner, U: 6 articles (01/2008 - 04/2000)|
|6.||Weiskirchen, Ralf: 5 articles (06/2014 - 03/2009)|
|7.||Mariani, G: 5 articles (03/2014 - 06/2005)|
|8.||Giansily-Blaizot, Muriel: 5 articles (04/2013 - 04/2002)|
|9.||Vettore, S: 5 articles (01/2013 - 07/2006)|
|10.||Pinotti, Mirko: 5 articles (03/2012 - 02/2002)|
06/01/2006 - "This report describes a case of possibly fatal bleeding treated successfully with an "overdose" of recombinant factor VII (rFVII; Novo7). "
08/01/2001 - "An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII."
07/01/1998 - "Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII."
02/01/2005 - "Activated recombinant factor VII may be a therapy that is potentially useful in the management of refractory bleeding after cardiac surgery and in other postoperative bleeding states. "
08/01/2011 - "The persistent hemorrhage improved following treatment, including transfusion, steroid therapy, and bypass therapy with factor VII formulations. "
09/14/2000 - "Our findings suggest that certain factor VII genotypes have a role in protection against myocardial infarction. "
02/01/2000 - "This intronic mutation, alone or in association with other factor VII gene polymorphisms, might confer protection against myocardial infarction in the young."
11/01/2014 - "[Study of the polymorphism R353Q in the coagulation factor VII gene and the N700S in the thrombospondin-1 gene in young patients with acute myocardial infarction]."
03/01/2010 - "High levels of coagulation factor VII (FVII) in plasma have been associated with the increased risk of myocardial infarction (MI) in some studies. "
09/01/2004 - "In this study, we investigate the influence of three factor VII (FVII) gene polymorphisms on activated FVII levels (FVIIa), and also on the risk of myocardial infarction (MI) in patients with advanced coronary atherosclerotic disease (CAD). "
12/01/2002 - "Circulating levels of Factor VII:C are determined by R353Q genotype and cluster with other risk factors associated with insulin resistance in South Asian ischaemic stroke patients, first-degree relatives and control subjects but are not related to stroke or a family history of stroke."
12/01/2002 - "Coagulation factor VII activity, Arg/Gln353 polymorphism and features of insulin resistance in first-degree-relatives of South Asian patients with stroke."
03/01/1996 - "Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus."
02/01/2010 - "Because increased adiposity enhanced the expression of coagulation factor VII that stimulates the coagulation pathway in adipose tissue, we tested whether the inhibition of thrombin action ameliorates insulin resistance in obese diabetic (Lpr(-/-):db/db) mice. "
01/01/2000 - "High factor VII activity was found in both groups with insulin resistance irrespective of their triglycerides level. "
03/01/2012 - "Rectus muscle sheath hematoma may occur in patients with factor VII (FVII)or FX deficiency. "
01/01/1991 - "Compared with the normal range for plasma, the hematoma fluids demonstrated a marked reduction in factors II, V, VII, VIII, and X, moderate reduction of factors IX and XI, and slight reduction of XII. Factor VII and IX inhibitors were not present or negligible. "
12/31/1976 - "Dermal provocations with grass pollens gave arthralgia, hematomas, serum C3 fluctuation, factor VII reduction and fibrinolysis. "
01/01/2006 - "While clinical studies continue to evaluate efficacy of activated recombinant factor VII (rFVlla) for reducing frequency of early hematoma growth, there have been no studies investigating the effect of rFVIIa on early hematoma growth. "
01/01/2006 - "We conducted this trial to evaluate the safety of activated recombinant factor VII (rFVIIa; NovoSeven) for preventing early hematoma growth in acute ICH. "
09/01/1990 - "It seems evident that factor VII concentrate would be effective in treating thrombocytopenia associated with type IIB vWD."
11/01/2014 - "[Using recombinant activated blood coagulation factor VII for treatment of hemorrhagic syndrome in patients with thrombocytopenia]."
09/20/1998 - "[New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate]."
02/15/2003 - "To test the efficacy of recombinant activated human coagulation factor VII (rFVIIa, NovoSeven) in thrombocytopenia, a preclinical study was conducted in thrombocytopenic rabbits. "
06/01/2015 - "The duration of action of both PCCs and plasma is six hours due to the short half-life of factor VII. Prothrombin complex concentrates contain small amounts of heparin and are contraindicated in patients with heparin-induced thrombocytopenia. "
|1.||recombinant FVIIa (rFVIIa)
|2.||Fibrinogen (Factor I)
|3.||Prothrombin (Factor II)
|4.||Plasminogen Activators (Plasminogen Activator)
|5.||Plasminogen Activator Inhibitor 1
|6.||Factor VIII (Coagulation Factor VIII)
|8.||Tissue Plasminogen Activator (Alteplase)
|1.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|4.||Homologous Transplantation (Allograft)
|5.||Photochemotherapy (Photodynamic Therapy)